Tevogen Bio Regains Nasdaq Compliance Following Reverse Stock Split
TVGN is trading near its 52-week low of $4.892 (7.1% above the low).
Summary
Tevogen Bio Holdings Inc. announced it has formally regained compliance with Nasdaq's minimum bid price requirement, a direct result of its recent 1-for-50 reverse stock split.
Key Events · Corporate Governance and Compliance · TVGN
-
Regained Nasdaq Compliance
On March 20, 2026, Tevogen Bio Holdings Inc. received written notice from The Nasdaq Stock Market LLC confirming it had regained compliance with Listing Rule 5450(a)(1) regarding the minimum bid price requirement.
-
Matter Closed
The Notification Letter indicates that the compliance matter is now closed, removing the immediate risk of delisting.
-
Result of Reverse Stock Split
This compliance was achieved following the implementation of a 1-for-50 reverse stock split, which became effective on March 6, 2026, as previously disclosed in a Form 8-K on March 4, 2026.
Analysis · TVGN · Life Sciences
This 8-K filing formally confirms Tevogen Bio Holdings Inc. has regained compliance with Nasdaq's minimum bid price requirement, removing an immediate delisting threat. This positive development follows a 1-for-50 reverse stock split, which was implemented to boost the share price above the $1.00 threshold. While reverse splits are often viewed negatively as a sign of distress, successfully regaining compliance provides stability and ensures the company's continued listing on The Nasdaq Global Market. This filing formalizes the news that was already reported by GlobeNewswire on March 25, 2026.
At the time of this filing, TVGN was trading at $5.24 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21M. The 52-week trading range was $4.89 to $75.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.